Journal of Cellular Physiology · 2009 · 308 citations · 27 references
Life SciencesCell BiologyPhysiologyCell DivisionCell ProliferationStem Cell BiologyAnimal Cell CultureCell Growth KineticsCellular Responses To HypoxiaHypoxia AdaptationStem Cell PhysiologyStem Cell ProliferationCell Proliferation KineticsEx Vivo Cell ExpansionEx Vivo Stem Cell ExpansionHypoxia-dependent GrowthHypoxia-induced MetabolismHypoxic MicroenvironmentMesenchymal Stem Cell ExpansionOxygen Tension Effects
The low bone marrow (BM) MSC titers demand a fast ex vivo expansion process to meet the clinically relevant cell dosage. Attending to the low oxygen tension of BM in vivo, we studied the influence of hypoxia on human BM MSC proliferation kinetics and metabolism. Human BM MSC cultured under 2% (hypoxia) and 20% O(2) (normoxia) were characterized in terms of proliferation, cell division kinetics and metabolic patterns. BM MSC cultures under hypoxia displayed an early start of the exponential growth phase, and cell numbers obtained at each time point throughout culture were consistently higher under low O(2), resulting in a higher fold increase after 12 days under hypoxia (40 +/- 10 vs. 30 +/- 6). Cell labeling with PKH26 allowed us to determine that after 2 days of culture, a significant higher cell number was already actively dividing under 2% compared to 20% O(2) and BM MSC expanded under low oxygen tension displayed consistently higher percentages of cells in the latest generations (generations 4-6) until the 5th day of culture. Cells under low O(2) presented higher specific consumption of nutrients, especially early in culture, but with lower specific production of inhibitory metabolites. Moreover, 2% O(2) favored CFU-F expansion, while maintaining BM MSC characteristic immunophenotype and differentiative potential. Our results demonstrated a more efficient BM MSC expansion at 2% O(2), compared to normoxic conditions, associated to an earlier start of cellular division and supported by an increase in cellular metabolism efficiency towards the maximization of cell yield for application in clinical settings.
27
Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease
Olle Ringdén, Mehmet Uzunel, Ida Rasmusson et al. · Transplantation · 2006 · 1.1K citations
David C. Colter, Ichiro Sekiya, Darwin J. Prockop · Proceedings of the National Academy of Sciences · 2001 · 943 citations · Full text
Aging of mesenchymal stem cell in vitro
Mandana Mohyeddin Bonab, Kamran Alimoghaddam, Fatemeh Talebian et al. · BMC Cell Biology · 2006 · 897 citations · Full text
Life Sciences, Cell Biology, Aging +16